JP2025111546A5 - - Google Patents

Info

Publication number
JP2025111546A5
JP2025111546A5 JP2025067565A JP2025067565A JP2025111546A5 JP 2025111546 A5 JP2025111546 A5 JP 2025111546A5 JP 2025067565 A JP2025067565 A JP 2025067565A JP 2025067565 A JP2025067565 A JP 2025067565A JP 2025111546 A5 JP2025111546 A5 JP 2025111546A5
Authority
JP
Japan
Prior art keywords
chimeric protein
targeting moiety
dendritic cells
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025067565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025111546A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/025419 external-priority patent/WO2020198659A1/en
Application filed filed Critical
Publication of JP2025111546A publication Critical patent/JP2025111546A/ja
Publication of JP2025111546A5 publication Critical patent/JP2025111546A5/ja
Pending legal-status Critical Current

Links

JP2025067565A 2019-03-28 2025-04-16 Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 Pending JP2025111546A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962825579P 2019-03-28 2019-03-28
US62/825,579 2019-03-28
PCT/US2020/025419 WO2020198659A1 (en) 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
JP2021558523A JP7749186B2 (ja) 2019-03-28 2020-03-27 Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021558523A Division JP7749186B2 (ja) 2019-03-28 2020-03-27 Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質

Publications (2)

Publication Number Publication Date
JP2025111546A JP2025111546A (ja) 2025-07-30
JP2025111546A5 true JP2025111546A5 (https=) 2025-12-04

Family

ID=72608957

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558523A Active JP7749186B2 (ja) 2019-03-28 2020-03-27 Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質
JP2025067565A Pending JP2025111546A (ja) 2019-03-28 2025-04-16 Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021558523A Active JP7749186B2 (ja) 2019-03-28 2020-03-27 Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質

Country Status (6)

Country Link
US (1) US20220185857A1 (https=)
EP (1) EP3946409A4 (https=)
JP (2) JP7749186B2 (https=)
CN (1) CN113645988A (https=)
CA (1) CA3133830A1 (https=)
WO (1) WO2020198659A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
CN114606227B (zh) * 2022-02-22 2024-03-08 复旦大学 高精度腺嘌呤碱基编辑器及其应用
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
PL333023A1 (en) * 1996-10-25 1999-11-08 Searle & Co Chimerical antagonists of haeomogenic multifunctional receptors
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
ES2694180T3 (es) * 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
JP6898325B2 (ja) * 2015-12-08 2021-07-07 ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ ＧＭ−ＣＳＦ遺伝子；Ｆｌｔ３Ｌ−ＴＲＡＩＬ融合遺伝子；ＴＧＦ−βの発現を抑制するｓｈＲＮＡ；およびＨＳＰ発現を抑制するｓｈＲＮＡを含む抗腫瘍組成物
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies

Similar Documents

Publication Publication Date Title
JP2025111546A5 (https=)
TWI250988B (en) Thrombopoietic compounds
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
Mizejewski Biological role of α-fetoprotein in cancer: prospects for anticancer therapy
ES2271004T3 (es) Uso de taci como agente antitumoral.
Sang et al. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation
US11926654B2 (en) Fusion proteins composed of an interleukin-2 mutein and type I interferon
EP2585098B1 (en) Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
WO2004026897A1 (ja) Ｗｔ１置換型ペプチド
JP7832111B2 (ja) Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP2013513377A5 (https=)
JP2005530716A (ja) ヒトにおける癌の治療方法
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
JP2023522588A5 (https=)
JP2023510870A5 (https=)
JP2022523024A5 (https=)
US20230242606A1 (en) Cxcl9 and variants thereof for immunotherapy of cancer diseases
MXPA06010655A (es) Citocina inmunosupresora.
AU2005298245B2 (en) A thymus-specific protein
JP2022527322A5 (https=)
KR20240164594A (ko) 설계된 사이토카인 조성물 및 사용 방법
JP2024514556A5 (https=)
JP2021531814A5 (https=)
WO1999019347A1 (en) Synthetic genes with immunomodulatory effects
CN116375880A (zh) 融合蛋白及其制备方法和应用